THERAPY DOSSIER · th-bd191390fabe

N(omega)-hydroxy-nor-L-arginine (nor-NOHA) arginase inhibitor, and Tie2-cre-mediated conditional deletion of Arg1

Drug

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Wound
Reported indication: Not recorded
First approval: Not recorded
Development stage: In trials, not approved
ChEMBL record: CHEMBL1234777 ↗
ChEMBL max phase: 1 / 4 (development scale, not regulatory approval)
Synonyms: J842.499C; N-hydroxy-nor-arginine; N-hydroxy-nor-l-arginine; N.omega.-hydroxy-nor-l-arginine; Nor-noha
Note: Not recorded

Clinical trials 4

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

NCT02687152 ↗PHASE1/PHASE2completed

Effect of Arginase Inhibition on Microvascular Endothelial Function in Patients With Type 2 Diabetes and Microvascular Dysfunction

Type 2 Diabetes Mellitus

Enrolment: 24 · Results not recorded

NCT05536934 ↗EARLY_PHASE1completed

Arginase Inhibition and Endothelial Function in Humans With Obesity

Obese · Endothelial Function

Enrolment: 15 · Results not recorded

NCT02009527 ↗PHASE1completed

Effect of Arginase Inhibition on Endothelial Function Induced by Ischemia-reperfusion in Patients With Coronary Artery Disease

Coronary Artery Disease · Type 2 Diabetes Mellitus

Enrolment: 24 · Results not recorded

NCT05806502 ↗NAcompleted

The Effect of Arginase Inhibition on Vascular Endothelial Function in Patients With Type 1 and Type 2 Diabetes

Type 1 Diabetes · Type 2 Diabetes

Enrolment: 12 · Results not recorded

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 23552798 ↗2013Reported harm

Local arginase 1 activity is required for cutaneous wound healing.

MouseWoundC57BL/6, Arg1 conditional allele crossed to Tie2-Cre (with littermate controls), plus ovariectomised and 18-month-old aged miceFemaleLocal injection into the wound (vehicle phosphate-buffered saline)nor-NOHA 20 micrograms per 50 microlitresInjected at day minus 1 and day 0 with respect to wounding

Model: Two equidistant 1 cm full-thickness incisional or 6 mm excisional skin wounds healing by secondary intention

Arginase activity peaked at 5 days post wounding. Pharmacological inhibition with nor-NOHA and Tie2-cre-mediated Arg1 deletion each delayed healing, with increased wound area, reduced re-epithelialisation, increased and prolonged macrophage and neutrophil influx, more iNOS positive cells, reduced c…

Extraction: extract · Supplied extraction confidence: 0.9. Machine-extracted fields require source verification.

Loading the evidence…